A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

  • End date
    Jul 23, 2039
  • participants needed
  • sponsor
Updated on 23 October 2022
renal function
ejection fraction
cytotoxic drug
systemic therapy
small molecule
squamous cell carcinoma
cytotoxic chemotherapy
epidermal growth factor receptor
mitomycin c
local ablation therapy


This is a first-in-human (FIH), Phase 1, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.


This is a first-in-human (FIH), Phase 1, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors. Refer to the Study Schema for a diagram of the study flow. After signing informed consent and completing all screening assessments, eligible subjects will undergo leukapheresis to obtain T cells for BOXR1030 manufacturing. Subjects will receive a 7-day LD chemotherapy regimen with fludarabine and cyclophosphamide, administered according to institutional standard practice for these drugs at this dosage, including inpatient administration as appropriate. Subjects must be hospitalized for BOXR1030 administration and will remain hospitalized for 10 days after the infusion. If at least 2 cohorts complete the dose-limiting toxicity (DLT) assessment period with no DLTs and no severe/delayed events of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), the Sponsor may allow subjects in subsequent cohorts to be discharged earlier, with daily follow-up clinic visits. For 28 days after BOXR1030 administration, all subjects must stay within a distance that requires no more than 2 hours of travel to the study site. During the Post-treatment Evaluation Period (6 months after BOXR1030 administration), study visits will occur daily for the first week, twice in the second week, and then at Weeks 3, 4, 6, and Months 2, 3, 4, 5, and 6. Safety (targeted physical examination, adverse event assessment, and clinical labs) will be evaluated and samples will be collected for endpoint analyses. For 28 days after BOXR1030 administration, subjects will be required to monitor their temperature and complete neurological evaluation via the immune effector cell-associated encephalopathy (ICE) assessment tool every day (to be administered by a caregiver at home on non-clinic days). At regular intervals, antitumor activity will be assessed per RECIST Version 1.1 and iRECIST criteria. After 6 months of follow-up from BOXR1030 administration, subjects will enter the Long-term Follow-up Period for a total duration of 15 years after BOXR1030 dosing. Study visits are scheduled every 3 months from Month 9 to Month 24, every 6 months thereafter until Year 5, and then annually through Year 15. Long-term follow-up assessments will focus on long-term safety and disease status.

Condition Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
Treatment CAR-GPC3 T Cells
Clinical Study IdentifierNCT05120271
Last Modified on23 October 2022


Yes No Not Sure

Inclusion Criteria

Aged 18 to 80 years at time of enrollment
Able to provide a recent tumor specimen taken since the time of the subject's most recent systemic anticancer therapy, for GPC3 expression assessment by IHC
Histologically confirmed advanced unresectable or metastatic hepatocellular carcinoma (HCC), squamous cell carcinoma (SCC) of the lung, myxoid/round cell iposarcoma (MRCLS), or Merkel cell carcinoma (MCC) with GPC3 overexpression by IHC. Subjects must consent to IHC testing in a separate informed consent. Note: Tumor samples will be sent to a central laboratory for GPC3 expression analysis
Documentation of disease progression or refractory disease or intolerance to prior lines of standard-of-care (SOC) therapies. Patients with tumors with genetic alterations and mutations (eg, breast cancer gene [BRCA], epidermal growth factor receptor [EGFR] mutations, and anaplastic lymphoma kinase [ALK] translocation) who have approved targeted therapies available for their cancer will need to have been treated with such approved therapies or refused such approved targeted therapy for their cancer prior to enrolling in this study
Life expectancy >16 weeks
Have adequate organ/renal function
Left ventricular ejection fraction (LVEF) ≥50% by multiple-gated acquisition (MUGA) scan or echocardiogram (ECHO)
Eastern Cooperative Group performance status of 0 to 1
For subjects with HCC
Child-Pugh Score of A
No fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma histology
No moderate or severe ascites
A minimum of 2 sites of disease, including at least 1 site that is measurable by
RECIST Version 1.1 criteria to ensure sufficient disease for response
assessment. At least 1 of the other lesions must be considered adequate for
protocol-required tumor biopsy. Consider prioritization of percutaneous
lesions that are palpable, or guided by imaging if necessary, and exclude
biopsies of any lesions that are in proximity to vital visceral, cardio-
pulmonary, or any neurovascular structures. A single site of disease is
considered adequate to allow for response assessment and protocol-required
tumor biopsies if it measures at least 2 cm in the shortest axis)
Adequate wash-out of prior systemic therapy for underlying malignancy, relative to
Last dose of any antineoplastic treatment must be at least 2 weeks before leukapheresis
Last dose of any investigational agent must be at least 3 half-lives of the treatment, or 28 days, before leukapheresis (whichever is shorter). Adequate wash-out of prior systemic therapy for underlying malignancy, relative to LD
The last dose of systemic nitrosourea or systemic mitomycin-C must be at least 6
weeks before the first dose of LD chemotherapy in this study
For all other for systemic cytotoxic chemotherapy, the wash-out must be the duration of a full cycle of that therapy. For example, if the prior therapy is given in 3-week cycles, there must be at least 3 weeks between the last dose of that therapy and the first dose of LD chemotherapy in this study. If the prior therapy is administered more frequently than every 2 weeks, a minimum 2-week wash-out is required
For biologic therapy (eg, antibodies) the wash-out must be either the duration of the biologic agent dosing interval, or 3 weeks, whichever is shorter
For small molecule therapies, the wash-out must be 5 half-lives of the drug
For any investigational agent, the wash-out must be 3 half-lives of the investigational agent, or 4 weeks, whichever is shorter
Note: Local radiation of lesions is allowed if indicated for palliation; locally
treated lesions will be considered non-target lesions. Hormone ablation is also
allowed as clinically indicated
Subjects or their legally acceptable representative must be able and willing to
Provide IRB/IEC-approved written informed consent in accordance with regulatory
and institutional guidelines. This must be obtained before the performance of any
protocol related procedures that are not part of normal patient care
Comply with the study protocol and with the planned biopsy procedures
Willing and able to commit to study assessments and visit schedule, including
availability of a caregiver to conduct daily neurological assessments for 28 days
after BOXR1030 administration
For women of childbearing potential (defined as physiologically capable of becoming
pregnant), confirmation of a negative serum pregnancy test and agreement to use of
highly effective contraception per Clinical Trials Facilitation and Coordination Group
(CTFG) criteria from screening through the first 12 months after BOXR1030
administration. For men with partners of childbearing potential, agreement to use
effective barrier contraception from screening through the first 12 months after
BOXR1030 administration

Exclusion Criteria

Prior treatment with adoptive cell therapy (eg, CAR T-cell therapy, natural killer
cell therapy, engineered T-cell receptor therapy)
History of allogenic hematopoietic stem cell transplant (HSCT)
Untreated central nervous system (CNS) tumors or brain metastasis. Patients are
eligible if CNS metastases are asymptomatic and have been treated and patients have
neurologically returned to baseline (residual signs or symptoms related to the CNS
treatment are permitted). Imaging obtained for the purpose of CNS metastases
management performed within 28 days prior to Day 1 must document radiographic
stability of CNS lesions and be performed after completion of any CNS directed
therapy. CNS evaluation for asymptomatic patients is not required for the study
Patients with leptomeningeal metastases are excluded
Patients who have not recovered to ≤ Grade 1 or baseline from all AEs due to previous
therapies (patients with ≤ Grade 2 neuropathy that has been stable for at least 4
weeks or ≤ Grade 2 endocrine-related AEs that has been stable for at least 4 weeks on
replacement therapy)
Planned use of any antineoplastic treatment or investigational agent from the time of
the first dose of LD chemotherapy through the end of study participation, except for
allowed local radiation of lesions for palliation (to be considered non-target lesions
after treatment) and hormone ablation
Uncontrolled or life-threatening symptomatic concomitant disease including clinically
significant gastrointestinal bleeding or pulmonary hemorrhage within 4 weeks before
screening, known symptomatic human immunodeficiency virus (HIV) positive with an
acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the
last year, or a current CD4 count <350 cells/uL, symptomatic active hepatitis B or C
checked at screening, or active tuberculosis. Patients with HIV are eligible if
They have received antiretroviral therapy (ART) as clinically indicated for at
least 4 weeks prior to starting study treatment
They continue on ART as clinically indicated while enrolled on study
CD4 counts and viral load are monitored per standard of care by a local health
care provider
Has undergone a major surgery within 3 weeks of starting study treatment or has
inadequate healing or recovery from complications of surgery prior to starting study
Has received prior radiotherapy within 2 weeks of start of study treatment. Subjects
must have recovered from all radiation-related toxicities, not require
corticosteroids, and not have had severe radiation pneumonitis. A 1-week wash-out is
permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease
Potentially life-threatening second malignancy requiring systemic treatment within the
last 3 years (ie, patients with a history of prior malignancy are eligible if
treatment was completed at least 3 years before entering the Treatment Period and the
patient has no evidence of disease) or which would impede evaluation of treatment
response. Hormone ablation therapy is allowed within the last 3 years. Patients with
history of prior early stage basal/squamous cell skin cancer or non-invasive or in
situ cancers that have undergone definitive treatment at any time are eligible
Clinically significant (ie, active) cardiovascular disease: cerebral vascular
accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months
prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart
Association Classification Class II), or the presence of any condition that can
increase proarrhythmic risk (eg, hypokalemia, bradycardia, heart block) including any
new, unstable, or serious cardiac arrhythmia requiring medication, or other baseline
arrhythmia that might interfere with interpretation of electrocardiograms (ECGs) on
study (eg, bundle branch block). Patients with QTcF >450 msec for males and >470 msec
for females on screening ECG are excluded. Any patients with a bundle branch block
will be excluded with QTcF >450 msec. Males who are on stable doses of concomitant
medication with known prolongation of QTcF (eg, selective serotonin re-uptake
inhibitor antidepressants) will only be excluded for QTcF >470 msec
Has an active infection requiring systemic therapy
A woman of child-bearing potential (WOCBP) who has a positive pregnancy test prior to
Is breastfeeding or expecting to conceive or father children within the projected
duration of the study, starting with the Screening Visit through 6 months after the
last dose of study treatment
Unable to receive any of the agents used in this study due to history of severe
immediate hypersensitivity reaction (eg, hypersensitivity to dimethyl sulfoxide
Known allergy or contraindication to any of the LD chemotherapy or prophylaxis
medications required during the study
Any other significant co-morbid disease or condition which, in the judgment of the
Investigator, would put the subject at undue risk (eg, cirrhotic liver disease)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note